chrisvoncsefalvay/vaers-outcomes huggingface dataset:
My stepfather on 31May2021 was diagnosed with Covid and right now has pneumonia; My stepfather on May 31 was diagnosed with Covid and right now has pneumonia; He had some trouble breathing; This is a spontaneous report from a Pfizer- sponsored program. A contactable consumer (Patients Stepchild) via medical information team. A 45-years-old male patient received bnt162b2 (BNT162B2; PFIZER-BIONTECH COVID-19 mRNA VACCINE, Batch/Lot number was not reported), via an unspecified route of administration, administered in arm right on 23May2021 (at the age of 45-years-old) as 1st dose, single dose for covid-19 immunisation. Medical history included arthritis from an unknown date and unknown if ongoing (it was a light condition. Arthritis was not getting worse he takes some medication). The patient's concomitant medications were not reported. The patient did not receive any other vaccines on the same day of vaccine vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within 2 weeks of vaccination. Prior to the vaccination, the patient did not have any adverse events. On 31May2021, the reporter stated that patient was diagnosed with Covid and right now had pneumonia. Patient went to the hospital 2 days after that. Patient had to go back to the hospital a second time because he had some trouble breathing (unknown date in 2021). After the second time going to the hospital was when he was diagnosed with pneumonia. Patient was diagnosed with pneumonia a week ago (unknown date in May2021). Patient still had pneumonia, but it was much better with the medication. The reporter clarified that the patient had COVID-19 PCR testing and it took 2 days for the results to come back and patient went to the hospital he was referring to the Emergency Room for trouble breathing. The patient underwent lab tests and procedures which included sars-cov-2 test: positive on 31May2021. Therapeutic measures were taken for the results of the event pneumonia. The events covid-19 and pneumonia assessed as serious. The clinical outcome of the event pneumonia was recovering and outcome of the other events was unknown. The patient scheduled to received second dose of Pfizer COVID Vaccine on 13Jun2021.  Follow-up attempts are needed; information about lot/batch number can be obtained.
She had a severe outbreak of herpes rash on her bottom that started several days ago; itching; uncomfortable; she has a drug called Acyclovir and she is wondering if that drug has been negative effect on her second dose of vaccine.; This is a spontaneous report from a contactable consumer. A 61-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 2 via an unspecified route of administration on 25Mar2021 (Batch/Lot number was not reported) as 2ND DOSE, SINGLE for covid-19 immunisation; and acyclovir sodium (ACYCLOVIR SODIUM), route of administration, start and stop date, batch/lot number and dose were not reported for an unspecified indication. Medical history included His wife has a history of herpes and tends to break out when she is nervous, upset, or anxious. The patient's concomitant medications were not reported. The patient received first dose of BNT162B2 for COVID-19 immunisation. On an unspecified date, she had a severe outbreak of herpes rash on her bottom that started several days ago.  It is usually only one spot but currently she has at least 3 or 4 spots.  It is itching and very uncomfortable. She typically uses acyclovir for breakouts but has not used it yet and just enduring the discomfort at the moment. The patient asked about the interaction between the Pfizer vaccine and acyclovir, she has a drug called Acyclovir and she is wondering if that drug has been negative effect on her second dose of vaccine. The outcome of the events was unknown.  Information about lot/batch no has been requested.
Patient reportedly became limp, pale and unresponsive. This episode lasted about 20-30 minutes and self resolved. She was seen in the ER then admitted overnight for observation. No further episodes noted. 2/10/06 - Review of d/c summary indicates final diagnosis of hypotonic-hyporesponsive episode.
13 days post MENVEO, c/o fatigue, muscle pain/weakness, sore throat, decreased ambulation. Seen ER & diagnosed with viral syndrome. Pt's symptoms lasted for 7 days. Some ataxia resolved. Exam always normal.
nausea; dizziness; aching all over the body; headache; fatigue.; sore arm; This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 61-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 4th September 2020, the patient received the 1st dose of Shingrix (intramuscular). On 4th September 2020, couple of hours after receiving Shingrix, the patient experienced pain in arm. On 7th September 2020, the patient experienced nausea, dizziness, general body pain, headache and fatigue. On an unknown date, the outcome of the pain in arm was unknown and the outcome of the nausea, dizziness, general body pain, headache and fatigue were not recovered/not resolved.   It was unknown if the reporter considered the pain in arm, nausea, dizziness, general body pain, headache and fatigue to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix and experienced a sore arm a few hours after the injection.  Three days after receiving vaccination, the patient experienced nausea, dizziness, aching all over the body, headache, and fatigue.   The patient shared that his sister's husband had unspecified adverse reactions and shared that his nurse reported unspecified adverse reactions to Shingrix as well.   There were no other details provided. The reporter consented to follow up. This case linked with US2020AMR181580 and US2020AMR181581, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR181580:same reporter (borther´s in law case) US-GLAXOSMITHKLINE-US2020AMR181581:same reporter (nurse case)
Fascial cellulitis and break through VZV. CT Scan left soft tissue edema; no abscess. Responded to Clondamycin. Failed OP.
Patient received FLUMIST on 10/09/2008.  Approx.  6 hrs later she developed hives on abdomen and a swollen lower lip.  seen in ER after giving BENADRYL and Sx then gone.
3/4/2021 1st vaccine-only sore arm 3 days 3/31/2021 2nd vaccine-Got Tired around 7:30pm (9.5 hrs after 2nd vaccine) went to bed, had night sweats, on/off chills, severe body aches, weirs sensation throughout body like something working veins mostly in legs, disoriented, arm pain, joint paint/stiff 4/1/2021 8AM took parents to Dr, 10AM had brkfst 11:30AM was back in bed felt like MAC TRUCK hit me or someone beat me with a bat all over especially legs. Weird dreams, tingling and aches through entire body, hard to walk like walking on air but feet sore, stayed in bed 36 hrs w/on/off chills, sore/swollen glands/lymphs, arm sore, loopy/disoriented woke up sweaty/clammy 4/2/2021 woke up 8AM w/mild sore arm/legs/loopy
sore throat; This is a spontaneous report from a contactable consumer (the patient). A male patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number not provided), via an unspecified route of administration on an unspecified date as a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient stated he was to receive the second dose, and he has had a sore throat for about 24 hours. He asked if he was still eligible to receive product (the second dose). The outcome of sore throat was not recovered.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Information has been received from a registered nurse concerning an adult patient, on dialysis, who was vaccinated with the primary series of RECOMBIVAX HB in the past (dates unspecified), is now is showing "negative titers". Unspecified medical attention was sought. There was no product quality complaint. At the time of reporting the patient was not yet recovered.  Attempts are being made to obtain additional identifying information to distinguish the individual patient mentioned in this report. Additional information will be provided if available. This is one of several reports received from the same source. Additional information has been requested.
No menstrual cycle since first injection; Tinnitus (constant ringing in both ears); Eczema flair ups (face); This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 26Mar2021 at 12:00(at the age of 44-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any medication within two weeks of vaccination. The patient previously took promethazine (PHENERGAN) and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021, since the first injection, the patient experienced no menstrual cycle, tinnitus (constant ringing in both ears), and eczema flair ups (face). The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of no menstrual cycle since first injection, tinnitus (constant ringing in both ears), eczema flair ups (face) and included treatment with unspecified medication from an unknown date, GP check up and OBGYN check up (ultrasound). On 24Jun2021, the patient underwent a nasal swab for Curative (PCR) test and the result was negative and on an unknown date the patient underwent an ultrasound and the result was unknown. The clinical outcome of the event no menstrual cycle since first injection, tinnitus (constant ringing in both ears), eczema flair ups (face) was not resolved at the time of this report.
Erythema at site of injection (8cm) vesicle formation (3.5cm) in central area & (L) axillary node.
Information has been received from a physician concerning a currently 23 year old female patient who at another doctor's office was vaccinated with the entire regimen of GARDASIL, intramuscularly, 0.5 ml all three doses (lot numbers not provided). There was no concomitant medication. On 30-JAN-2012, the patient after having a pap smear, it was found to have atypia cells. On 23-FEB-2012, the patient had a colposcopy done and it revealed moderate dysplasia. The results also came back positive for P16. The patient sought medical attention. Treatment for the adverse event included a "leep" performed on 13-MAR-2012 (results pending). The patient was working with their health care provider to address the situation. At the time of the report, the patient had not recovered (ongoing). Follow-up information has been received from a physician who reported that the female medical assistant patient with no pre-existing allergies, birth defects or medical conditions and no illness at the time of vaccination and unknown events following prior vaccination on 10-JUL-2007 was vaccinated with a first 0.5 ml dose of GARDASIL (Lot # 0323D not valid lot # for GARDASIL), IM, at unknown time. On 12-SEP-2007 was vaccinated with a second 0.5ml dose of GARDASIL (Lot # 658222/0927U), IM, in the right deltoid at unknown time and on 18-JAN-2008, was vaccinated with a third 0.5ml dose of GARDASIL (Lot# 1268U, not valid lot # for GARDASIL), IM, Right deltoid, at unknown time. The physician stated that the patient received the series of GARDSAIL and the patient was not sexually active at that time. She has since been diagnosed with Human papilloma virus (HPV) and labs showed high grade of dysplasia. A cervical smear, surgical pathology of colposcopies and LEEP procedure were performed not results provided. At the time of reporting, the patient's outcome was unknown. The events Moderate dysplasia (High grade dysplasia), Positive for P16 and Human papilloma virus (HPV) were considered to be an important medical events by the physician. (according to the reporter the events required medical/surgical intervention to prevent one of the outcomes listed). Additional information has been requested.
PATIENT REFERS SHE BEGAN WITH WHEEZING AND DIFICULTY BREATHING AFTER VACCINE ADMINISTRATION.
general body weakness few hours p/vax was given;MOC did not bring minor to PMD as instructed;states only called PMD & was advised to stay home;
Within 12 hours of my father's second Pfizer covid vaccine, he lost complete use of his legs. OVERNIGHT. He also began to hallucinate, which we suspected was due to a UTI but even after the UTI cleared, his hallucinations got worse. These two adverse events put him on a steady, relatively fast downward path and he died on 03/26/2021.
Information has been received from a physician concerning a female patient of 7 months old who on 22-OCT-2012, was vaccinated with GARDASIL accidentally. No other co-suspects were reported. Concomitant medications included PEDIARIX, ROTATEQ and PREVNAR 13. There was no reported adverse reactions. The outcome of inappropriate age at vaccine administration was unknown. Additional information has been requested.
Approximately 5 minutes after the vaccination, patient experienced syncope (lightheadedness, low blood pressure, pale and fainting). Her father requested emergency medical services. EMS arrived, and evaluated her blood pressure, heart rate, and blood sugar (all within normal limits). They determined patient was safe to return home. Total time of adverse event thru evaluation (5:15 pm to 5:45 pm).
Mom called 6-28-10 child taken to ER due to hives no wheeze.  ER dx generalized hives tx orapred BENADRYL.  Child seen by Dr at health dept 6-29-10.  No wheeze, hives cheeks, thigh, upper arms, treatment BENADRYL.  Nurse called father 7-1-10 child better, hives resolving.
pt recv vax 15 or 16AUG97 & in 1997 pt devel varicella w/many lesions although less than 50 on the upper trunk, face & arms;
Pt has a rash that has been expanding.  She is also feeling a lot of pain.
Limp, blank stare, within the hour of the shot, jerking some later in the day.
Redness in upper right arm Hot - warm to the touch Hard Tender to touch Itchy
He started off with a sore throat and it progressed into really bad congestion; headache; earache and fatigue. No fever. Ibuprofen was given for headache and throat lozenges for his throat. He drank a lot of water. It lasted four days. He started to feel better. The congestion hung around about a full week before he had no more congestion. He got sick first and then his little brother followed and then I got sick - we were all sick about the same amount of time - 5- 7 days. His Dad got his second shot at the same time as patient got his first shot. I had been fully vaccinated by that time.
SHOT WAS ADMINISTERED TOO HIGH, AT THE VERY TOP INTO THE THIN MUSCLE OF MY DELTOID AND AT A 45 DEGREE ANGLE, CONFIRMED BY URGENT CARE DOCTOR.  SEEMS TO HAVE MISSED THE JOINT BUT I CANNOT MOVE MY ARM WITHOUT SEVERE PAIN.  RECEIVED PRESCRIPTION FOR FLEXERIL.  STILL IN SEVERE PAIN AS OF THREE DAYS LATER.  URGENT CARE DOCTOR SAID THIS SHOULD NOT HAVE HAPPENED AND IS THE RESULT OF IMPROPER TRAINING OR TECHNIQUE.
Began with chills & fatigue, progressed to diarrhea. Then body aches, fever, chills, nausea, vomiting, ...lasted about 3 hours.  Then fatigue, headache, chills which lasted about 18 hours. Treated with Tylenol 500mg after vomit and during headache feeling.
(L) deltoid erythema and edema 90x100 mm, hot to touch.
I woke up on 8/1/2021 (1 week after vaccination shot) with mild itching and redness at the injection site. It is a raised, red area approximately 3 inches in diameter. No soreness, but it is ?hot.? No other issues.
This case was reported by a consumer via call center representative and described the occurrence of dry cough in a 79-year-old male patient who received SHINGRIX. On 16th March 2018 14:00, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. In March 2018, less than a week after receiving SHINGRIX, the patient experienced wheezing. On 16th March 2018, the patient experienced dry cough, dry heaves, chilliness and spasms. On 23rd March 2018, the patient experienced exercise capacity decreased. On 22nd March 2018, the outcome of the dry cough was resolved with sequelae. On an unknown date, the outcome of the dry heaves and wheezing were recovering/resolving and the outcome of the exercise capacity decreased, chillness and spasms were unknown. The reporter considered the dry cough, dry heaves, exercise capacity decreased, wheezing, chillness and spasms to be almost certainly related to SHINGRIX. Additional information was received as follows: When the patient was in the office after receiving the vaccine, he felt chilly. On the way to home, the patient developed a dry cough, but because the patient was used to gets such types of cough periodically, he did not considered dry cough serious. When the patient went home after 30 minutes, the cough had become more pronounced and the patient was told that it was coming from his lungs. On 16th March 2018, the cough was worsen during the night and the patient described it as a spasm type of cough that the patient could not control. Cough caused the patient to have dry heaves and reports that the cough was worse when he laid in certain positions. The patient was thought about going to the emergency room but he did not. On 17th March 2018 and 18th March 2018, the patient still had the cough but it was not as bad as it was on 16th March 2018. On 19th March 2018, the patient saw his physician and his lung function and oxygen levels were all normal. On 22nd March 2018, Thursday or Friday, 23rd March 2018, although he felt he had been left with wheezing. The wheezing was getting less and less daily. On 23rd March 2018, the patient exercised with his trainer and noted that he was not able to accomplish the same goals as he accomplished the week before due to the wheeze. Reporter gave permission for his physician to be contacted and provided the information.
Headache; insomnia; Minimal arm pain for both doses; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 48 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 19Jan2021 08:30 (Lot number: EL8982) at the age of 48 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "known allergies: shellfish" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious) with onset Jan2021, outcome "recovered" (2021), described as "Minimal arm pain for both doses"; HEADACHE (non-serious) with onset 19Jan2021, outcome "recovered" (2021), described as "Headache"; INSOMNIA (non-serious) with onset 19Jan2021, outcome "recovered" (2021), described as "insomnia". Therapeutic measures were not taken as a result of pain in extremity, headache, insomnia.  Additional information: Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Patient also received second dose on 09Feb2021.  No follow-up attempts are possible. No further information is expected.
Bumpy, red rash covering shoulders, upper back, and part of chest. Some bumps are like small pimples. This showed up 2 days after vaccination. It is so what itchy but not terribly so.
Patient fainted about three minutes post vaccination. She complained of being  very dizzy, blurry  and being a little warm. She denied any trouble breathing or any sings of tightness of the throat. She was able to verbalize and answer any questions. Patient was observed for any worsening of symptoms for about 30minutes. She appeared to be ok at the time she left the pharmacy.
Patient fainted for a few seconds within a few minutes of vaccination.  Within 5 seconds he was talking but still had loss of color.  Removed sweatshirt.  Immediately gave ice packs and stuck ammonia inhalant under his nose to help.   His color improved after 5 minutes.  Patient stayed in pharmacy area for thirty minutes.  He then played in a soccer game a few hours later and was continuing to do fine.
cotton mouth; This spontaneous case was reported by a consumer and describes the occurrence of DRY MOUTH (cotton mouth) in a 28-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012H21B) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Dec-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Dec-2021, the patient experienced DRY MOUTH (cotton mouth). At the time of the report, DRY MOUTH (cotton mouth) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported. No treatment medications were reported.
This study case was received from the investigator in the trial on 31 January 2013. A 21-year-old male subject had received the ACAM2000 (lot number, route and site not reported) on 14 January 2013. The subject had also received the following vaccinations in December 2012 on an unknown day: anthrax vaccine (manufacturer, lot number, route and site not reported) and influenza vaccine (manufacturer, lot number, route and site not reported). On 24 January 2013, the subject with a negative cardiac history and prednisone allergy presented with onset of constant chest pain, chest pressure, shortness of breath, and heart palpitations, all with the onset date of 16 January 2013 and ongoing, and all were considered possibly related by investigator. The chest pain felt "consolidated" in the middle of the chest and did not radiate. Nothing made the symptom better or worse. On the Wong-Baker FACES Pain Rating Scale, the subject reported a rating of 2 out of 5 for chest pain. The chest pressure was centralized and did not get better or worse and did not radiate. The subject also experienced headache on 14 January 2013 (possibly related), itching around the vaccine site on 18 January 2013 (very likely related), and swollen lymph node on left axilla vaccine side on 21 January 2013 (very likely related). These events were all ongoing. The subject was taking concomitant medications ibuprofen since 23 January 2013 for swollen lymph node and BENADRYL since 23 January 2013 for itching around vaccine site. The rapid and lab troponin and electrocardiogram (ECG) were normal on 24 January 2013. The subject did not feel like he had a cold or flu. The subject's outcome was not recovered. According to the investigator, the event of possible myopericarditis was considered possibly related to vaccination. Documents held by sender: None.
rt leg swollen et bright red from groin to knee, hot to touch;used cold compresses;improved next high pitched cry for 45mins, episode of not breathing;grandma flicked pt on feet;
6'2", 200 POUND 16Y/O MALE RECEIVED MODERNA VACCINE. MOM IS ENROLLING HIM IN VSAFE. SHE IS AWARE THAT HIS NEXT DOSE IN 4 WEEKS WILL ALSO BE MODERNA
Myalgia, Arthralgia, Fever, NauseaVomiting, L arm inj site pain and chills lasted 48 hours Narrative:  Other Relevant History: